Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Ann Palliat Med ; 11(4): 1231-1240, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: covidwho-1560745

RESUMEN

BACKGROUND: The purpose of this study was to investigate the current status of diagnosis and treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) and the expert recommendation of the therapeutic regimens during the coronavirus disease 2019 (COVID-19) pandemic, and to analyze and summarize relevant rules. METHODS: Under the planning and coordination of the Lung Cancer Group of the Chinese Thoracic Society, we performed an online questionnaire survey among experts in lung cancer and patients with NSCLC. Convenience sampling was adopted for questionnaire survey of experts, and random sampling was adopted for questionnaire survey of patients. After collecting and sorting out the questionnaire, a descriptive analysis of the data was performed. RESULTS: Within 24 h from the distribution of questionnaires to the deadline, a total of 808 and 321 valid questionnaires from patients and experts were collected across China, respectively. There were 83.81% of the experts performed moderately and strongly anti-tumor therapy for patients with NSCLC during the COVID-19 pandemic. 76.6% of patients mainly receive online public welfare treatment, and the patient satisfaction rate reached up to 64.97%. For driver gene-positive patients with advanced NSCLC and non-COVID-19, 82.87% of the experts recommended first-line simple targeted therapy, and 12.77% of the experts recommended targeted therapy with oral anti-angiogenic drugs. For patients who were unable to return to the hospital for treatment and showed resistance to the tyrosine kinase inhibitor (TKI) therapy, 92.21% of the experts recommended oral anti-angiogenic drugs as the third-line home-based therapy and above. For patients with advanced NSCLC combined with COVID-19, 98.76% and 95.95% of the experts recommended discontinuation of chemotherapy and immunotherapy, respectively. CONCLUSIONS: During COVID-19, most Chinese patients with NSCLC were still able to receive timely diagnosis and treatment either by online public welfare consultation or at nearby hospitals.


Asunto(s)
COVID-19 , Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Inhibidores de la Angiogénesis/uso terapéutico , COVID-19/epidemiología , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/terapia , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/terapia , Pandemias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA